The risk factors, pathophysiology, and burden of disease for hepatorenal syndrome– acute kidney injury (HRS-AKI)
The importance of early recognition, current diagnosis and treatment recommendations for HRS-AKI
Clinical data that led to the FDA approval of TERLIVAZ
Speakers
Farid ArmanMD
Attending Physician, University of California, Los Angeles
Clinical Instructor, University of California, Los Angeles, Center for Health Sciences
Los Angeles, CA
